| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01180231 | Obesity|Overweight | Drug: Moxonidine (Physiotens)|Other: Dietary intervention | Baker IDI Heart and Diabetes Institute | Phase 4 | 2010-09-01 | 2013-11-03 |
| NCT00244504 | Cardiac Disease|Vascular Surgery | Drug: moxonidine | University Hospital, Basel, Switzerland | Phase 3 | 2002-11-01 | 2009-11-09 |
| NCT02355821 | Osteopenia|Arterial Hypertension | Drug: Moxonidine|Drug: Bisoprolol | National Research Center for Preventive Medicine | | 2015-04-01 | 2016-09-20 |
| NCT00160277 | Hypertension | Drug: Moxonidine | Solvay Pharmaceuticals | Phase 3 | 2005-07-01 | 2009-01-29 |
| NCT01360710 | Abdominal Obesity|Hypertension | Drug: Moxonidine|Drug: Irbesartan | Baker IDI Heart and Diabetes Institute | Phase 4 | 2012-01-01 | 2012-02-01 |
| NCT01791699 | Atrial Fibrillation | Drug: Moxonidine|Drug: Placebo | Spyridon Deftereos|G.Gennimatas General Hospital | Phase 4 | 2012-08-01 | 2014-05-04 |
| NCT01094769 | Diabetic Nephropathies | Drug: Moxonidine|Drug: Placebo | Baker IDI Heart and Diabetes Institute | Phase 4 | 2011-04-01 | 2013-12-16 |
| NCT01567124 | Schizophrenia | Drug: Moxonidine|Drug: Placebo|Drug: Moxonidine|Drug: Placebo | Baker IDI Heart and Diabetes Institute|The Alfred|Monash Medical Centre|Ballarat Health Services | Phase 4 | 2012-05-01 | 2013-12-16 |
| NCT01504321 | Polycystic Ovary Syndrome | Drug: Moxonidine|Drug: Placebo | Baker IDI Heart and Diabetes Institute | Phase 4 | 2012-05-01 | 2016-01-11 |
| NCT01138423 | Hypertension|Abdominal Obesity|Metabolic Syndrome | Drug: Aliskiren|Drug: Moxonidine|Drug: Hydrochlorothiazide|Drug: Placebo (for aliskiren)|Drug: Placebo (for moxonidine and hydrochlorothiazide) | UMC Utrecht|Novartis Pharmaceuticals | Phase 4 | 2010-08-01 | 2012-02-23 |
| NCT00160160 | Hypertension|Type 2 Diabetes | Drug: eprosartan/HCTZ | Solvay Pharmaceuticals | | 2004-10-01 | 2009-01-29 |
| NCT00518479 | Hypertension|Left Ventricular Hypertrophy | Drug: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD|Drug: Valsartan 160mg OD; Moxonidine 400mcg OD | University of Leeds|The Leeds Teaching Hospitals NHS Trust | | 2003-09-01 | 2012-08-15 |
| NCT00424801 | Microvascular Angina|Hypertension | Drug: Lercanidipine|Drug: Valsartan|Drug: Nicorandil|Drug: Doxazosin|Drug: Moxonidin|Drug: Pindolol|Drug: Amiloride, hydrochlorothiazide | University of Aarhus|Danish Cardiovascular Research Academy|Danish Heart Foundation|Novartis | 2007-01-01 | 2009-05-05 |
| NCT02734290 | Triple Negative Breast Cancer | Drug: Pembrolizumab|Drug: Paclitaxel|Drug: Capecitabine | Providence Health & Services|Merck Sharp & Dohme Corp. | Phase 1|Phase 2 | 2016-05-01 | 2016-07-27 |
| NCT02950259 | Breast Neoplasm|Breast Neoplasm, Male | Drug: Cyclophosphamide|Drug: Indomethacin|Drug: Omeprazole|Dietary Supplement: Multivitamin | Providence Health & Services|IRX Therapeutics | Phase 1 | 2017-02-09 | 2017-03-01 |
| NCT01862900 | Metastatic Breast Cancer|Lung Metastases|Liver Metastases | Biological: MEDI6469 | Providence Health & Services|Robert W. Franz Cancer Center|Providence Cancer Center|Providence Cancer Center, Earle A. Chiles Research Institute|MedImmune LLC | Phase 1|Phase 2 | 2013-02-01 | 2016-06-23 |
| NCT02614794 | HER2 Positive Breast Cancer | Drug: Tucatinib|Drug: Capecitabine|Drug: Trastuzumab|Drug: Placebo | Cascadian Therapeutics Inc. | Phase 2 | 2015-12-01 | 2016-12-23 |
| NCT02037529 | Metastatic Breast Cancer|Locally Recurrent Breast Cancer | Drug: Eribulin|Drug: Paclitaxel | Academic and Community Cancer Research United | Phase 3 | 2014-03-01 | 2017-03-15 |
